Compare · BDSX vs ELV
BDSX vs ELV
Side-by-side comparison of Biodesix Inc. (BDSX) and Elevance Health Inc. (ELV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDSX and ELV operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $92.91B, about 356.4x BDSX ($260.7M).
- Both names hit the wire about 3 times in the past 4 weeks.
- ELV has more recent analyst coverage (23 ratings vs 9 for BDSX).
- Company
- Biodesix Inc.
- Elevance Health Inc.
- Price
- -
- -
- Market cap
- $260.7M
- $92.91B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 3
- 3
- Recent ratings
- 9
- 23
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Latest BDSX
- Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026
- Chairman Patience John converted options into 1,360 shares, increasing direct ownership by 5% to 26,743 units (SEC Form 4)
- Biodesix Advances Two Complementary Approaches to Molecular Residual Disease (MRD) Monitoring
- Biodesix Quality and Regulatory Executive, Brianna Phillips, to speak at upcoming RAPS and SOCRA Annual Meetings
- Biodesix to Participate in Upcoming Investor Conferences
- Emeritus Director Schuler Jack W bought $366,992 worth of shares (15,000 units at $24.47) (SEC Form 4)
- Emeritus Director Schuler Jack W bought $665,940 worth of shares (27,600 units at $24.13) (SEC Form 4)
- SEC Form 10-Q filed by Biodesix Inc.
- Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biodesix Announces Second Quarter 2026 Results and Highlights
Latest ELV
- SEC Form 4 filed by Elevance Health Inc.
- Elevance Health to Hold Conference Call and Webcast to Discuss Third Quarter 2026 Results on October 21, 2026
- Elevance Health’s Affiliated 2027 Medicare Advantage Plans Advance Stability, Choice and More Coordinated Support
- Elevance Health Inc. filed SEC Form 8-K: Regulation FD Disclosure
- EVP & Chief Legal Officer Wessling Erin M covered exercise/tax liability with 349 shares, decreasing direct ownership by 5% to 7,230 units (SEC Form 4)
- EVP & Chief HR Officer Craig Ryan R covered exercise/tax liability with 144 shares, decreasing direct ownership by 2% to 6,530 units (SEC Form 4)
- Elevance Health Strengthens Connected Cancer Care Model to Support Consumers Through Their Health Journey
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.